Literature DB >> 8870628

The UK register of HIV seroconverters: methods and analytical issues. UK register of HIV seroconverters (UKRHS) Steering Committee.

.   

Abstract

A Register of HIV-infected persons who have had a negative antibody test within 3 years of their first antibody positive test (seroconverters) is being set up in the UK to monitor the distribution of times from HIV seroconversion to AIDS (the incubation period) and to death. It will also provide a national resource for use by those designing studies in this group of individuals. Clinicians caring for HIV-positive persons in Genito-Urinary Medicine, Infectious Disease and other departments throughout the UK were asked to participate by providing information on eligible subjects. Most laboratories undertaking HIV antibody testing were also contacted and asked to provide the name of the attending clinician for all seroconverters identified through the HIV laboratory reporting systems of the PHLS Communicable Disease Surveillance Centre (CDSC) and the Scottish Centre for Infection and Environmental Health (SCIEH) and for any other seroconverters known to them but not identified by CDSC or SCIEH. Data items sought for the Register include: sex, ethnic group, probable route of HIV transmission, annual CD4 counts, details of therapy and prophylaxis prescribed, AIDS-defining events and vital status. Follow up information is collected annually. Wherever possible, all seroconverters known to a clinic have been identified, whether currently alive or dead, either from clinic records or laboratory reporting or both. The objective is to establish and update a complete register of seroconverters on a long-term to basis to provide reliable estimates of the incubation period on which future projections of AIDS cases in the UK can be made.

Entities:  

Mesh:

Year:  1996        PMID: 8870628      PMCID: PMC2271712          DOI: 10.1017/s0950268800001485

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  24 in total

1.  Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS.

Authors:  W Lang; H Perkins; R E Anderson; R Royce; N Jewell; W Winkelstein
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

2.  Effects of long-term seropositivity to human immunodeficiency virus in a cohort of homosexual men.

Authors:  M T Schechter; W J Boyko; K J Craib; A McLeod; B Willoughby; B Douglas; P Constance; M O'Shaughnessey
Journal:  AIDS       Date:  1987-07       Impact factor: 4.177

3.  The treatment-free incubation period of AIDS in a cohort of homosexual men.

Authors:  J C Hendriks; G F Medley; G J van Griensven; R A Coutinho; S H Heisterkamp; H A van Druten
Journal:  AIDS       Date:  1993-02       Impact factor: 4.177

4.  Effect of age at seroconversion on the natural AIDS incubation distribution. Multicenter Hemophilia Cohort Study and the International Registry of Seroconverters.

Authors:  P S Rosenberg; J J Goedert; R J Biggar
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

5.  CD4 lymphocyte counts within 24 months of human immunodeficiency virus seroconversion. Findings in the US Navy and Marine Corps. The Navy Retroviral Working Group.

Authors:  E D Gorham; F C Garland; D L Mayers; R R Goforth; S K Brodine; P J Wiess; M S McNally
Journal:  Arch Intern Med       Date:  1993-04-12

6.  Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study.

Authors:  P J Veugelers; K A Page; B Tindall; M T Schechter; A R Moss; W W Winkelstein; D A Cooper; K J Craib; E Charlebois; R A Coutinho
Journal:  Am J Epidemiol       Date:  1994-10-15       Impact factor: 4.897

7.  HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.

Authors:  A Cozzi Lepri; P Pezzotti; M Dorrucci; A N Phillips; G Rezza
Journal:  BMJ       Date:  1994-12-10

8.  Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centres in the United Kingdom.

Authors:  S C Darby; C R Rizza; R Doll; R J Spooner; I M Stratton; B Thakrar
Journal:  BMJ       Date:  1989-04-22

9.  Use of CD4 lymphocyte count to predict long-term survival free of AIDS after HIV infection.

Authors:  A N Phillips; C A Sabin; J Elford; M Bofill; G Janossy; C A Lee
Journal:  BMJ       Date:  1994-07-30

10.  The Edinburgh City Hospital cohort: analysis of enrollment, progression and mortality by baseline covariates.

Authors:  R P Brettle; A J McNeil; S M Gore; A G Bird; C S Leen; A Richardson
Journal:  QJM       Date:  1995-07
View more
  7 in total

1.  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

Authors:  Maile Ray; Roger Logan; Jonathan A C Sterne; Sonia Hernández-Díaz; James M Robins; Caroline Sabin; Loveleen Bansi; Ard van Sighem; Frank de Wolf; Dominique Costagliola; Emilie Lanoy; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casbona; Julia del Amo; Santiago Moreno; Amy Justice; Joseph Goulet; Sara Lodi; Andrew Phillips; Rémonie Seng; Laurence Meyer; Santiago Pérez-Hoyos; Patricia García de Olalla; Miguel A Hernán
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

2.  When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

Authors:  Lauren E Cain; Roger Logan; James M Robins; Jonathan A C Sterne; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; Ard van Sighem; Frank de Wolf; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casabona; Julia del Amo; Santiago Moreno; Remonie Seng; Laurence Meyer; Santiago Perez-Hoyos; Roberto Muga; Sara Lodi; Emilie Lanoy; Dominique Costagliola; Miguel A Hernan
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

3.  The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.

Authors:  Jamie Inshaw; Clifford Leen; Martin Fisher; Richard Gilson; David Hawkins; Simon Collins; Julie Fox; Ken McLean; Sarah Fidler; Andrew Phillips; Sam Lattimore; Abdel Babiker; Kholoud Porter
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

4.  Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.

Authors:  Sara Lodi; Andrew Phillips; Sarah Fidler; David Hawkins; Richard Gilson; Ken McLean; Martin Fisher; Frank Post; Anne M Johnson; Louise Walker-Nthenda; David Dunn; Kholoud Porter
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

5.  Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection.

Authors:  John Thornhill; Jamie Inshaw; Pontiano Kaleebu; David Cooper; Gita Ramjee; Mauro Schechter; Giuseppe Tambussi; Julie Fox; Miriam Samuel; Jose M Miro; Jonathan Weber; Kholoud Porter; Sarah Fidler
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

6.  A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England.

Authors:  Annabelle Gourlay; Julie Fox; Mitzy Gafos; Sarah Fidler; Nneka Nwokolo; Amanda Clarke; Richard Gilson; Chloe Orkin; Simon Collins; Kholoud Porter; Graham Hart
Journal:  BMJ Open       Date:  2017-08-28       Impact factor: 2.692

7.  Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV.

Authors:  Oliver T Stirrup; Caroline A Sabin; Andrew N Phillips; Ian Williams; Duncan Churchill; Anna Tostevin; Teresa Hill; David T Dunn
Journal:  J Virus Erad       Date:  2019-11-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.